

Audited Consolidated Statement of Comprehensive Income

According to IFRS

<i>Thousands of Euro (€) except per share amounts</i>	Year ended December 31, 2009	Year ended December 31, 2008
Product and service income	1,031	1,403
Government grant income	1,517	1,621
Revenues	2,548	3,024
Cost of goods & services sold	179	243
Gross profit	2,369	2,781
Research and development expenses	13,089	10,999
Selling, general and administrative expenses	4,011	3,107
Other operating income	0	0
Other operating expenses	0	1
Total operating charges	17,100	14,107
Operating Profit (EBIT)	(14,731)	(11,326)
Financial income	450	1,143
Financial expenses	20	9
Profit/(Loss) before taxes	(14,301)	(10,192)
Income taxes	0	0
Net Profit/(Loss) for the year from continuing operations	(14,301)	(10,192)
Profit/(Loss) for the year from discontinued operations	0	0
Profit/(Loss) for the year from continuing operations	(14,301)	(10,192)
Other comprehensive income		
Exchange differences arising on translation of foreign operations	0	(43)
Other comprehensive income for the year (net of tax)	0	(43)
Total comprehensive profit/(loss) for the year (net of tax)	(14,301)	(10,235)

Basic earnings per share (EPS) €

Using weighted average number of shares	(1.09)	(0.86)
Using end of period number of shares	(1.08)	(0.77)

Audited Consolidated Statement of Financial Position

According to IFRS

<i>Thousands of Euro (€)</i>	Year ended December 31, 2009	Year ended December 31, 2008
ASSETS		
Intangible assets	49	1,644
Property, plant and equipment	1,022	1,429
Financial assets	500	500
Grants receivable (> 1 year)	405	1,087
Non-current assets	1,976	4,660
Grants receivable (< 1 year)	2,674	2,412
Trade receivables	533	369
Prepaid expenses and other current assets	1,537	1,010
Cash and cash equivalents	18,032	30,601
Current assets	22,776	34,392
TOTAL ASSETS	24,752	39,052
EQUITY AND LIABILITIES		
Share capital	51,089	50,989
Issuance premium	10,882	10,872
Accumulated profit/(loss)	(30,842)	(20,650)
Result of the year	(14,301)	(10,192)
Share-based compensation	1,981	1,633
Translation reserves	(9)	(9)
Total equity	18,800	32,643
Grants payable (> 1 year)	406	1,088
Advance on royalties	151	164
Long-term lease debt	0	0
Non-current liabilities	557	1,252
Current portion of lease debt	0	1
Trade payables	2,681	2,524
Grants payable (< 1 year)	1,162	1,953
Other current liabilities	1,552	679
Current liabilities	5,395	5,157
TOTAL EQUITY AND LIABILITIES	24,752	39,052

Audited Consolidated Cash Flow Statement

According to IFRS

<i>Thousands of Euro (€)</i>	Year ended December 31, 2009	Year ended December 31, 2008
CASH FLOWS FROM OPERATING ACTIVITIES		
Operating Profit/(Loss)	(14,731)	(11,326)
Depreciation, amortization and impairment results	2,298	1,004
Share-based compensation	348	281
Interest paid	0	(3)
(Increase)/decrease in accounts receivable (1)	(256)	102
Increase/(decrease) in account payable (2)	(457)	629
Total adjustments	1,933	2,013
Net cash provided by/(used in) operating activities	(12,798)	(9,313)
CASH FLOWS FROM INVESTING ACTIVITIES		
Investment in financial assets	0	(500)
Interest received	434	1,075
Other financial profit/(loss)	(20)	62
Purchase of property, plant and equipment	(261)	(223)
Purchase of intangible assets	(35)	(2,033)
Net cash provided by/(used in) investing activities	118	(1,619)
CASH FLOWS FROM FINANCING ACTIVITIES		
Payments on long-term leases	(1)	(2)
Proceeds from issuance of shares (net of issue costs)	110	8,475
Net cash provided by/(used in) financing activities	109	8,473
Net increase/(decrease) in cash and cash equivalents	(12,571)	(2,459)
Cash and cash equivalents at beginning of year	30,601	33,103
Effect on Exchange rate changes	2	(43)
Cash and cash equivalents at end of period	18,032	30,601



OncoMethylome Sciences SA
 Full Year 2009 Financial Results
 as of Dec. 31, 2009

Audited Consolidated Statement of changes in shareholders' equity
 According to IFRS

<i>Thousands of Euro (€)</i>	Attributable to equity holders of the Company					
	Number of shares	Share capital & issuance premium	Retained earnings	Share-based compensation	Translation reserves	Total equity
Balance at January 1, 2008	11,747,702	53,386	(20,650)	1,352	34	34,122
Total comprehensive income			(10,192)		(43)	(10,235)
Issuance of shares	1,413,372	8,756				8,756
SPO costs against capital		(281)				(281)
Share-based compensation				281		281
Balance at December 31, 2008	13,161,074	61,861	(30,842)	1,633	(9)	32,643
Balance at January 1, 2009	13,161,074	61,861	(30,842)	1,633	(9)	32,643
Total comprehensive income			(14,301)		0	(14,301)
Issuance of shares	24,540	110				110
Share-based compensation				348		348
Balance at December 31, 2009	13,185,614	61,971	(45,143)	1,981	(9)	18,800